ClinicalTrials.gg
TerminatedNCT05900050Updated Jul 23, 2026Results posted

Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®

A Phase 2 interventional study of VS-01 on top of SOC and SOC (Control Group) in Acute-On-Chronic Liver Failure and Ascites, sponsored by Genfit. Terminated at 26 sites in 7 countries. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by Genfit · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Study summary

A Phase 2, multi-center, randomized, controlled, open-label study to evaluate the effects of the intraperitoneal, liposomal formulation VS-01 in patients with an acute episode of hepatic and/or extrahepatic organ dysfunctions and failures in the presence of liver cirrhosis (Acute-on-Chronic Liver Failure, ACLF) and accumulation of fluid in the abdominal cavity (ascites)

02

Conditions studied

  • Acute-On-Chronic Liver Failure
  • Ascites

Keywords

  • Chronic liver diseases
  • Hepatic Dysfunction
  • Extrahepatic Organ Dysfunction
  • Liver Failure
  • Renal Disease
  • Hepatic Impairment
  • Renal Impairment
  • Hepatic Decompensation
  • Cirrhosis
03

In context

Acute-On-Chronic Liver Failure

167 studies on the registry are indexed under Acute-On-Chronic Liver Failure; 61 are open to participants now.

This study's enrollment of 15 is below the median of 73 across 96 interventional studies indexed under Acute-On-Chronic Liver Failure.

Browse Acute-On-Chronic Liver Failure studies →

Lead sponsor

Genfit is the lead sponsor of 23 studies on the registry; 2 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with ACLF Grade 1, 2, or 3a according to European Association for the Study of the Liver (EASL)-CLIF criteria;
  2. Onset of ACLF not more than 14 days before Baseline (BL);
  3. Presence of ascites requiring diagnostic or therapeutic paracentesis;
  4. Patients with dry body weight ≥40 and \<140 kg;
  5. Written obtained prior to the start of any study-related procedures.

Exclusion criteria

Exclusion Criteria:

  1. Presence of any of the following organ failure(s) as per the EASL-CLIF criteria and/or adapted from CLIF-C Organ Failure (CLIF-C OF)/CLIF- Sequential Organ Failure Assessment (CLIF-SOFA) scores:

    1. Respiratory failure necessitating invasive mechanical ventilation;
    2. Coagulation failure ( > 3.2 or count ≤20 x 109/L);
    3. Severe cardiovascular failure requiring the use of high dose vasopressors;
  2. ACLF grade 3b: Presence of four or more organ failures as per EASL CLIF criteria;
  3. Presence of spontaneous or secondary bacterial peritonitis;
  4. Presence of uncontrolled severe infection(with hemodynamic instability or shock);
  5. Poorly controlled seizure disorder;
  6. Patients with history of upper gastro-intestinal bleeding over the past 7 days prior to BL, acute bleeding or bleeding upon paracentesis at screening (SCR) or BL;
  7. for paracentesis;
  8. Coagulation disorders such as disseminated intravascular coagulation or hemophilia;
  9. Potential or known to liposomes;
  10. Potential or known risk factors for allergic/anaphylactoid like reactions (e.g., mastocytosis/elevated basal tryptase) or multiple hypersensitivities;
  11. Patients after organ transplantation receiving medication;
  12. Any severe disease considered to be potentially detrimental at the discretion of the Principal Investigator. This includes but is not limited to hepatocellular carcinoma outside Milan criteria, cholangiocarcinoma, extrahepatic cancer over the past 2 years or people who inject drugs;
  13. Need for Renal Replacement Therapy or any extracorporeal liver support device (e.g., MARS®, Prometheus®, plasmapheresis);
  14. Alfapump® in place to manage ascites;
  15. Pregnancy and lactation;
  16. Women of who are not willing to use adequate ;
  17. Patients who participate in another clinical trial at the time of SCR or within 4 weeks prior to SCR.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    VS-01 on top of SOC (Active Treatment Group)

    Patients randomized to Active Treatment group will receive VS-01 on top of SOC

    Drug: VS-01 on top of SOC

  • Other
    SOC (Control Group)

    Patients randomized to Control group will receive SOC defined as the standard medical management of patients with decompensated cirrhosis and ACLF

    Other: SOC (Control Group)

Interventions

  • DrugVS-01 on top of SOC

    Patients will receive VS-01 intraperitoneally on four consecutive days on top of SOC

  • OtherSOC (Control Group)

    Patients will receive SOC for decompensated cirrhosis and ACLF

06

What researchers measure

Primary outcomes

  1. Chronic Liver Failure Consortium (CLIF-C) ACLF Score at Day 7

    The CLIF-C ACLF score is derived from the CLIF-C organ failure (OF) score. The formula for the CLIF-C ACLF score is CLIF-ACLF = 10\*\[0.33\*CLIF-C OF + 0.04\*Age + 0.63\*Ln(white cell count) -2\]. The CLIF-C ACLF score ranges from 0-100, where a higher score indicated a greater mortality risk.

    Time frame: Day 7

Secondary outcomes

  1. Number of Deaths From Day 1 to Day 90

    90-Day mortality was reported as the number of deaths from Day 1 to Day 90.

    Time frame: Day 1 to Day 90

  2. Number of Deaths From Day 1 to Day 28

    28-Day mortality was reported as the number of deaths from Day 1 to Day 28.

    Time frame: Day 1 to Day 28

  3. Time to Death Through Day 90

    Time to death was calculated as death date - treatment start date. Participants who were not observed to have encountered the event through Day 90 were censored. The inter-quartile range was obtained via Kaplan Meier estimation.

    Time frame: Day 1 to Day 90

  4. Number of Participants With ACLF Resolution

    ACLF resolution was defined as ACLF grade 'No ACLF', for participants who had ACLF at Baseline.

    Time frame: Baseline to Day 7 and Day 28

  5. Time to ACLF Resolution Through Day 28

    ACLF resolution was defined as ACLF grade 'No ACLF', for participants who had ACLF at Baseline. Time to ACLF resolution was calculated as (ACLF resolution date - treatment start date). Participants who were not observed to have encountered the event through Day 28 were censored at min\[trial discontinuation date; Day 28 visit date or treatment start date +27 if no visit date; last contact/assessment date for participant lost to follow-up; date of liver transplant or transjugular intrahepatic portosystemic shunt (TIPS)\]. The inter-quartile range was obtained via Kaplan Meier estimation.

    Time frame: Baseline to Day 28

  6. Number of Participants With ≥ 1 ACLF Grade Regression

    ACLF regression was defined as regression of at least one full grade.

    Time frame: Baseline, Day 7 and Day 28

  7. Time to ≥ 1 ACLF Grade Regression Through Day 28

    Time to ACLF ≥ 1 grade regression was calculated as (ACLF ≥ 1 grade regression date - treatment start date). Participants who were not observed to have encountered the event through Day 28 were censored. The inter-quartile range was obtained via Kaplan Meier estimation.

    Time frame: Baseline and Day 28

  8. Secondary: Time to Transplant or Death Through Day 90

    Time to transplant was calculated as (transplant or death date - treatment start date). Participants who were not observed to have encountered the event through Day 90 were censored. The inter-quartile range was obtained via Kaplan Meier estimation.

    Time frame: Day 1 through Day 90

  9. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An AE was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a study drug and that does not necessarily have a causal relationship with this treatment. A TEAE was the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after at least one dose of the study drug had been administered, even if the event was not considered to be related to the study drug. A serious AE (SAE) was any untoward medical event that occurs at any dose that: resulted in death; was life-threatening; required in-patient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect; or was an important medical event.

    Time frame: Up to Day 90

07

Results

Posted Jul 23, 2026
Limitations and caveats
Due to premature discontinuation of the trial and the limited sample size, all analyses were descriptive. No inferential statistical testing was performed, and no formal conclusions can be drawn.

Participant flow

A total of 15 participants were enrolled into this trial in the United States, Germany and France between July 2023 and October 2025.

Participant flow — Overall Study
MilestoneActive Treatment Group: VS-01 on Top of Standard of Care (SOC)Control Group: SOC Alone
Started96
Completed32
Not completed64
Withdrew: Death42
Withdrew: Liver transplant20
Withdrew: Withdrawal of consent01
Withdrew: Lost to follow-up01

Outcome measures

PrimaryChronic Liver Failure Consortium (CLIF-C) ACLF Score at Day 7

The CLIF-C ACLF score is derived from the CLIF-C organ failure (OF) score. The formula for the CLIF-C ACLF score is CLIF-ACLF = 10\*\[0.33\*CLIF-C OF + 0.04\*Age + 0.63\*Ln(white cell count) -2\]. The CLIF-C ACLF score ranges from 0-100, where a higher score indicated a greater mortality risk.

Time frame:
Day 7
Reported as:
Mean · score on a scale
Chronic Liver Failure Consortium (CLIF-C) ACLF Score at Day 7
score on a scaleActive Treatment Group: VS-01 on Top of SOCControl Group: SOC Alone
Chronic Liver Failure Consortium (CLIF-C) ACLF Score at Day 750.852 ± 15.545939.866 ± 6.3557
SecondaryNumber of Deaths From Day 1 to Day 90

90-Day mortality was reported as the number of deaths from Day 1 to Day 90.

Time frame:
Day 1 to Day 90
Reported as:
Count of participants · Participants
Number of Deaths From Day 1 to Day 90
ParticipantsActive Treatment Group: VS-01 on Top of SOCControl Group: SOC Alone
Number of Deaths From Day 1 to Day 9041
SecondaryNumber of Deaths From Day 1 to Day 28

28-Day mortality was reported as the number of deaths from Day 1 to Day 28.

Time frame:
Day 1 to Day 28
Reported as:
Count of participants · Participants
Number of Deaths From Day 1 to Day 28
ParticipantsActive Treatment Group: VS-01 on Top of SOCControl Group: SOC Alone
Number of Deaths From Day 1 to Day 2840
SecondaryTime to Death Through Day 90

Time to death was calculated as death date - treatment start date. Participants who were not observed to have encountered the event through Day 90 were censored. The inter-quartile range was obtained via Kaplan Meier estimation.

Time frame:
Day 1 to Day 90
Reported as:
Median · days
Time to Death Through Day 90
daysActive Treatment Group: VS-01 on Top of SOCControl Group: SOC Alone
Time to Death Through Day 90NA (18 to —)NA
SecondaryNumber of Participants With ACLF Resolution

ACLF resolution was defined as ACLF grade 'No ACLF', for participants who had ACLF at Baseline.

Time frame:
Baseline to Day 7 and Day 28
Reported as:
Count of participants · Participants
Number of Participants With ACLF Resolution
ParticipantsActive Treatment Group: VS-01 on Top of SOCControl Group: SOC Alone
Day 7 — Resolution11
Day 7 — No Resolution22
Day 28 — Resolution12
Day 28 — No Resolution21
SecondaryTime to ACLF Resolution Through Day 28

ACLF resolution was defined as ACLF grade 'No ACLF', for participants who had ACLF at Baseline. Time to ACLF resolution was calculated as (ACLF resolution date - treatment start date). Participants who were not observed to have encountered the event through Day 28 were censored at min\[trial discontinuation date; Day 28 visit date or treatment start date +27 if no visit date; last contact/assessment date for participant lost to follow-up; date of liver transplant or transjugular intrahepatic portosystemic shunt (TIPS)\]. The inter-quartile range was obtained via Kaplan Meier estimation.

Time frame:
Baseline to Day 28
Reported as:
Median · days
Time to ACLF Resolution Through Day 28
daysActive Treatment Group: VS-01 on Top of SOCControl Group: SOC Alone
Time to ACLF Resolution Through Day 28NA (3 to —)13 (5 to —)
SecondaryNumber of Participants With ≥ 1 ACLF Grade Regression

ACLF regression was defined as regression of at least one full grade.

Time frame:
Baseline, Day 7 and Day 28
Reported as:
Count of participants · Participants
Number of Participants With ≥ 1 ACLF Grade Regression
ParticipantsActive Treatment Group: VS-01 on Top of SOCControl Group: SOC Alone
Day 7 — Regression11
Day 7 — No Regression85
Day 28 — Regression12
Day 28 — No Regression84
SecondaryTime to ≥ 1 ACLF Grade Regression Through Day 28

Time to ACLF ≥ 1 grade regression was calculated as (ACLF ≥ 1 grade regression date - treatment start date). Participants who were not observed to have encountered the event through Day 28 were censored. The inter-quartile range was obtained via Kaplan Meier estimation.

Time frame:
Baseline and Day 28
Reported as:
Median · days
Time to ≥ 1 ACLF Grade Regression Through Day 28
daysActive Treatment Group: VS-01 on Top of SOCControl Group: SOC Alone
Time to ≥ 1 ACLF Grade Regression Through Day 28NANA (13 to —)
SecondarySecondary: Time to Transplant or Death Through Day 90

Time to transplant was calculated as (transplant or death date - treatment start date). Participants who were not observed to have encountered the event through Day 90 were censored. The inter-quartile range was obtained via Kaplan Meier estimation.

Time frame:
Day 1 through Day 90
Reported as:
Median · days
Secondary: Time to Transplant or Death Through Day 90
daysActive Treatment Group: VS-01 on Top of SOCControl Group: SOC Alone
Death22 (18 to —)NA
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An AE was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a study drug and that does not necessarily have a causal relationship with this treatment. A TEAE was the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after at least one dose of the study drug had been administered, even if the event was not considered to be related to the study drug. A serious AE (SAE) was any untoward medical event that occurs at any dose that: resulted in death; was life-threatening; required in-patient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect; or was an important medical event.

Time frame:
Up to Day 90
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsActive Treatment Group: VS-01 on Top of SOCControl Group: SOC Alone
Any TEAEs96
Any Grade 3 or Higher TEAEs85
Any TEAEs Related to VS-016NA
Any Serious TEAEs75
Any Serious TEAEs Related to VS-012NA

Adverse events

Collected over Up to Day 90. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active Treatment Group: VS-01 on Top of SOC4/9 (44.4%)7/9 (77.8%)9/9 (100%)
Control Group: SOC Alone2/6 (33.3%)5/6 (83.3%)6/6 (100%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventActive Treatment Group: VS-01 on Top of SOCControl Group: SOC Alone
Hepatic encephalopathyNervous system disorders2/90/6
Chronic hepatic failureHepatobiliary disorders1/91/6
Hepatic cirrhosisHepatobiliary disorders1/91/6
PneumoniaInfections and infestations0/91/6
Disturbance in attentionNervous system disorders0/91/6
Gastrointestinal haemorrhageGastrointestinal disorders1/91/6
Pleural effusionRespiratory, thoracic and mediastinal disorders0/91/6
HyponatraemiaMetabolism and nutrition disorders0/91/6
Mental status changesPsychiatric disorders0/91/6
Acute on chronic liver failureHepatobiliary disorders1/90/6
Most frequent other events
Showing 10 of 71
Most frequent other events
EventActive Treatment Group: VS-01 on Top of SOCControl Group: SOC Alone
HypocalcaemiaMetabolism and nutrition disorders3/90/6
HypokalaemiaMetabolism and nutrition disorders1/92/6
DiarrhoeaGastrointestinal disorders2/92/6
AnaemiaBlood and lymphatic system disorders1/92/6
HyperkalaemiaMetabolism and nutrition disorders2/90/6
HypomagnesaemiaMetabolism and nutrition disorders2/90/6
PneumoniaInfections and infestations2/91/6
EncephalopathyNervous system disorders2/90/6
SyncopeNervous system disorders2/90/6
Acute kidney injuryRenal and urinary disorders2/90/6

Baseline characteristics

Full Analysis Set (FAS): All randomized participants.

Age, Continuous
Age, Continuous(years)Active Treatment Group: VS-01 on Top of SOCControl Group: SOC AloneTotal
Mean56.59 ± 8.21051.18 ± 11.29554.43 ± 9.571
Sex: Female, Male
Sex: Female, Male(Participants)Active Treatment Group: VS-01 on Top of SOCControl Group: SOC AloneTotal
Female033
Male9312
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Active Treatment Group: VS-01 on Top of SOCControl Group: SOC AloneTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American112
White6511
More than one race000
Unknown or Not Reported202
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Active Treatment Group: VS-01 on Top of SOCControl Group: SOC AloneTotal
Hispanic or Latino101
Not Hispanic or Latino6612
Unknown or Not Reported202
08

Study locations

26 sites
  • University of California Davis Medical Center
    Sacramento, California 95817, United States
  • Medstar Georgetown University Hospital
    Washington D.C., District of Columbia 20007, United States
  • Tampa General Hospital
    Tampa, Florida 33606, United States
  • Piedmont Atlanta Hospital
    Atlanta, Georgia 30309, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • University of Missouri Health Care
    Columbia, Missouri 65212, United States
  • Columbia University Medical Center/ New York Presbyterian Hospital
    New York, New York 10032, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • The Liver Institute at Methodist Dallas
    Dallas, Texas 75203, United States
  • Baylor Clinic
    Houston, Texas 77030, United States
  • Richmond VA Medical Center
    Richmond, Virginia 23249, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • Universitair Ziekenhuis Antwerpen
    Edegem, 2650, Belgium
  • Centre Hospitalier Régional Universitaire de Tours
    Chambray-lès-Tours, 37170, France
  • Hôpital de la Croix Rousse
    Lyon, 69004, France
  • Hôpital Universitaire Pitié Salpêtrière
    Paris, 75013, France
  • CHU Rennes - Hôpital Pontchaillou
    Rennes, 35033, France
  • Universitatsklinikum Munster
    Münster, North Rhine-Westphalia 48149, Germany
  • Charité Universitätsmedizin Berlin
    Berlin, State of Berlin 13353, Germany
  • Medizinische Hochschule Hannover
    Hanover, 30625, Germany
  • Debreceni Egyetem Klinikai Központ
    Debrecen, 4032, Hungary
  • Heves Vármegyei Markhot Ferenc Oktatókórház és Rendelőintézet
    Eger, 3300, Hungary
  • ASST Grande Ospedale Metropolitano Niguarda
    Milan, 20162, Italy
  • Azienda Ospedaliero-Universitaria Policlinico Umberto I
    Roma, 00185, Italy
  • Hospital Clínic de Barcelona
    Barcelona, Barcelona 08036, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Oct 2025, 27 months.

Results were first posted in Jul 2026, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2023
First posted
Jun 12, 2023
StartActual
Jul 2, 2023
Primary completionActual
Oct 15, 2025
CompletionActual
Oct 15, 2025
Results first posted
Jul 23, 2026
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05900050
Lead sponsor
Genfit
Responsible party
Sponsor
First posted
Jun 12, 2023
Start date
Jul 2, 2023
Primary completion
Oct 15, 2025
Completion
Oct 15, 2025
Results posted
Jul 23, 2026
Last update
Jul 23, 2026

Study contacts

Pejvack MOTLAGH, M.D, M.Sc
study director · Genfit

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion